In the Literature

Standard pediatric chemotherapy regimens used in the treatment of children and adolescents with high-risk Hodgkin lymphoma are often associated with late effects, including second cancers, infertility, and cardiovascular disease, as well as significantly reduced overall survival (OS). Read More ›

Induction chemotherapy leads to remission in many patients with acute myeloid leukemia (AML) aged ≥60 years; however, the disease relapses in most patients, resulting in poor overall survival (OS). Read More ›

  • Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
  • Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
  • Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read More ›

  • Selinexor-Dexamethasone Combination Improves Outcomes in Patients with Multiple Myeloma Refractory to 3 Drug Classes
  • Five-Year Survival Rates with BRAF-MEK Inhibitors in Metastatic Melanoma with BRAF Mutation
Read More ›

  • New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
  • Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
  • Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
Read More ›

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. Read More ›

  • Venetoclax plus Rituximab Improves Outcomes in Chronic Lymphocytic Leukemia
  • Lay Navigation Reduces Medicare Costs, Resource Utilization
  • Adding Antiandrogen Therapy Improves Survival in Recurrent Prostate Cancer
Read More ›

  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Mutations Responsible for Relapse Despite PD-1 Therapy Uncovered in Melanoma
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
Read More ›

  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Enzalutamide Superior to Bicalutamide in Patients with Prostate Cancer
Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: